Sensyne Health and the University of Oxford’s Big Data Institute (BDI) have announced plans to establish a world-leading research alliance, using data science and clinical artificial intelligence (clinical AI) for the patient-centred management and treatment of chronic disease.
The news came as Sensyne also revealed plans to enter a strategic research agreement with both the George Eliot Hospital NHS Trust - giving the company access to datasets covering 746,000 hospital admissions, and the Wye Valley NHS Trust - a partnership which will provides access to anonymised patient datasets covering 1.36 million hospital admissions, both for analysis using clinical artificial intelligence technology.
Both trusts will receive a £2.5 million equity stake in Sensyne Health, at a price of £1.75 per share, and will also benefit from royalties that arise from any discoveries.
The unique three-year alliance between the groups aims to advance the analysis and interpretation of unique NHS datasets in chronic kidney disease and cardiovascular disease, using clinical AI to improve care and accelerate the discovery and development of new medicines.
The research programme will draw on BDI’s expertise in population health, clinical informatics and machine learning. It will also be facilitated by access to anonymised longitudinal datasets for those patients in the NHS Trusts which builds on Sensyne Health’s existing capabilities through its Clinical AI and Strategic Research Agreements.
Lord Paul Drayson, chief executive of Sensyne Health, said of the partnership: “This new collaboration with the BDI is designed to apply world-class data science to the growing burden of chronic disease on society, and create an effective partnership between the NHS, industry and academia that delivers scalable improvements to patient care, accelerates the discovery and development of new medicines and shares the commercial value created with our partner NHS Trusts and the University of Oxford.”